Methods Design: Randomized controlled trial (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in

Does Rivaroxaban Better than Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing PCI?

Maamar Kara
Omar Aitmokhtar
Adel Azaza
Saber Seddiki
Faiza Harbi
Arezki Sik
Kheireddine Merad
Salim Benkhedda

December 2016

ACS: Acute Coronary Syndrome; AF: Atrial Fibrillation; DAPT: Dual Antiplatelet Therapy; INR: Interna...

Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial

김영대

October 2017

Importance: In atrial fibrillation (AF)-related acute ischemic stroke, the optimal oral anticoagula...

Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.

Gibson, C.M.
Mega, J.L.
Burton, P.
Goto, S.
Verheugt, F.W.A.
Bode, C.
Plotnikov, A.
Sun, X.
Cook-Bruns, N.
Braunwald, E.

January 2011

BACKGROUND: Although therapy with aspirin or aspirin plus a thienopyridine reduces the incidence of ...

Replication of rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation in a cohort study using electronic primary care database

Althunian, Turki A.I.
De Boer, Anthonius
Groenwold, Rolf H.H.
Rengerink, Katrien O.
Souverein, Patrick C.
Klungel, Olaf H.

August 2019

Background: Imitating the design of a randomized controlled trial in an observational study is one o...

January 1739

AF) trial, the efficacy and safety of rivaroxaban, a novel, oral, direct factor Xa inhibitor, was as...

Background: In ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct

Daniel E. Singer
Prevention Of Stroke
Embolism Trial
Atrial Fibrillation

November 2015

large randomized, clinical trial, rivaroxaban was noninferior to war-farin in preventing stroke or s...

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation

Turpie AGG

March 2014

Alexander GG Turpie Department of Medicine, McMaster University, Hamilton, ONT, Canada Abstract: At...

Methods Design: Randomized placebo-controlled trial. ClinicalTrials.gov

November 2015

Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving wa...

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Patel, Manesh R
Mahaffey, Kenneth W
Garg, Jyotsna
Pan, Guohua
Singer, Daniel E
Hacke, Werner
Breithardt, Günter
Halperin, Jonathan L
Hankey, Graeme J
Piccini, Jonathan P
Becker, Richard C
Nessel, Christopher C
Paolini, John F
Berkowitz, Scott D
Fox, Keith a A
Califf, Robert M
Renseigné, Non

September 2011

International audienceBACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patient...

Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial

Hart R. G.
Sharma M.
Mundl H.
Shoamanesh A.
Kasner S. E.
Berkowitz S. D.
Pare G.
Kirsch B.
Pogue J.
Pater C.
Peters G.
Davalos A.
Lang W.
Wang Y.
Wang Y.
Cunha L.
Eckstein J.
Tatlisumak T.
Shamalov N.
Mikulik R.
Lavados P.
Hankey G. J.
Czlonkowska A.
Toni D.
Ameriso S. F.
Gagliardi R. J.
Amarenco P.
Bereczki D.
Uchiyama S.
Lindgren A.
Endres M.
Brouns R.
Yoon B. -W.
Ntaios G.
Veltkamp R.
Muir K. W.
Ozturk S.
Arauz A.
Bornstein N.
Bryer A.
O'Donnell M. J.
Weitz J.
Peacock F.
Themeles E.
Connolly S. J.

January 2016

Background: Embolic strokes of undetermined source comprise up to 20% of ischemic strokes. The strok...

Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source : Design of the NAVIGATE ESUS randomized trial

Hart, Robert G.
Sharma, Mukul
Mundl, Hardi
Shoamanesh, Ashkan
Kasner, Scott E.
Berkowitz, Scott D.
Pare, Guillaume
Kirsch, Bodo
Pogue, Janice
Pater, Calin
Peters, Gary
Davalos, Antoni
Lang, Wilfried
Wang, Yilong
Cunha, Luis
Eckstein, Jens
Tatlisumak, Turgut
Shamalov, Nikolay
Mikulik, Robert
Lavados, Pablo
Hankey, Graeme J.
Czlonkowska, Anna
Toni, Danilo
Ameriso, Sebastian F.
Gagliardi, Rubens J.
Amarenco, Pierre
Bereczki, Daniel
Uchiyama, Shinichiro
Lindgren, Arne
Endres, Matthias
Brouns, Raf
Yoon, Byung Woo
Ntaios, George
Veltkamp, Roland
Muir, Keith W.
Ozturk, Serefnur
Arauz, Antonio
Bornstein, Natan
Bryer, Alan
O’Donnell, Martin J.
Weitz, Jeffrey
Peacock, Frank
Themeles, Ellison
Connolly, Stuart J.

January 2016

Background: Embolic strokes of undetermined source comprise up to 20% of ischemic strokes. The strok...

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.

Camm, AJ
Amarenco, P
Haas, S
Hess, S
Kirchhof, P
van Eickels, M
Turpie, AG

July 2014

Atrial fibrillation (AF) is associated with a fivefold increase in the risk of stroke. The Phase III...

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)

Gibson, C.M.
Mehran, R.
Bode, C.
Halperin, J.
Verheugt, F.W.A.
Wildgoose, P.
Eickels, M. van
Lip, G.Y.
Cohen, M.
Husted, S.
Peterson, E.
Fox, K.

January 2015

BACKGROUND: Guidelines recommendations regarding anticoagulant therapy after percutaneous coronary i...

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF

Hankey, GJ
Patel, MR
Stevens, SR
Becker, RC
Breithardt, G
Carolei, A
Diener, H-C
Donnan, GA
Halperin, JL
Mahaffey, KW
Mas, J-L
Massaro, A
Norrving, B
Nessel, CC
Paolini, JF
Roine, RO
Singer, DE
Wong, L
Califf, RM
Fox, KAA
Hacke, W

April 2012

C1 - Journal Articles RefereedBACKGROUND: In ROCKET AF, rivaroxaban was non-inferior to adjusted-dos...

Rivaroxabán versus warfarina en la fibrilación auricular no valvular

Patel, Manesh
Mahaffey, Kenneth
Garg, Jyotsna
Pan, Guohua
Singer, Daniel
Hacke, Werner
Breithardt, Gunter
Halperin, Jonathan
Hankey, Graeme
Piccini, Jonathan
Becker, Richard
Nessel, Christopher

August 2020

BACKGROUND The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillat...

Does Rivaroxaban Better than Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing PCI?

Maamar Kara
Omar Aitmokhtar
Adel Azaza
Saber Seddiki
Faiza Harbi
Arezki Sik
Kheireddine Merad
Salim Benkhedda

December 2016

ACS: Acute Coronary Syndrome; AF: Atrial Fibrillation; DAPT: Dual Antiplatelet Therapy; INR: Interna...

Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial

김영대

October 2017

Importance: In atrial fibrillation (AF)-related acute ischemic stroke, the optimal oral anticoagula...

Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.

Gibson, C.M.
Mega, J.L.
Burton, P.
Goto, S.
Verheugt, F.W.A.
Bode, C.
Plotnikov, A.
Sun, X.
Cook-Bruns, N.
Braunwald, E.

January 2011

BACKGROUND: Although therapy with aspirin or aspirin plus a thienopyridine reduces the incidence of ...

Replication of rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation in a cohort study using electronic primary care database

Althunian, Turki A.I.
De Boer, Anthonius
Groenwold, Rolf H.H.
Rengerink, Katrien O.
Souverein, Patrick C.
Klungel, Olaf H.

August 2019

Background: Imitating the design of a randomized controlled trial in an observational study is one o...

January 1739

AF) trial, the efficacy and safety of rivaroxaban, a novel, oral, direct factor Xa inhibitor, was as...

Background: In ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct

Daniel E. Singer
Prevention Of Stroke
Embolism Trial
Atrial Fibrillation

November 2015

large randomized, clinical trial, rivaroxaban was noninferior to war-farin in preventing stroke or s...

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation

Turpie AGG

March 2014

Alexander GG Turpie Department of Medicine, McMaster University, Hamilton, ONT, Canada Abstract: At...

Methods Design: Randomized placebo-controlled trial. ClinicalTrials.gov

November 2015

Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving wa...

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Patel, Manesh R
Mahaffey, Kenneth W
Garg, Jyotsna
Pan, Guohua
Singer, Daniel E
Hacke, Werner
Breithardt, Günter
Halperin, Jonathan L
Hankey, Graeme J
Piccini, Jonathan P
Becker, Richard C
Nessel, Christopher C
Paolini, John F
Berkowitz, Scott D
Fox, Keith a A
Califf, Robert M
Renseigné, Non

September 2011

International audienceBACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patient...

Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial

Hart R. G.
Sharma M.
Mundl H.
Shoamanesh A.
Kasner S. E.
Berkowitz S. D.
Pare G.
Kirsch B.
Pogue J.
Pater C.
Peters G.
Davalos A.
Lang W.
Wang Y.
Wang Y.
Cunha L.
Eckstein J.
Tatlisumak T.
Shamalov N.
Mikulik R.
Lavados P.
Hankey G. J.
Czlonkowska A.
Toni D.
Ameriso S. F.
Gagliardi R. J.
Amarenco P.
Bereczki D.
Uchiyama S.
Lindgren A.
Endres M.
Brouns R.
Yoon B. -W.
Ntaios G.
Veltkamp R.
Muir K. W.
Ozturk S.
Arauz A.
Bornstein N.
Bryer A.
O'Donnell M. J.
Weitz J.
Peacock F.
Themeles E.
Connolly S. J.

January 2016

Background: Embolic strokes of undetermined source comprise up to 20% of ischemic strokes. The strok...

Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source : Design of the NAVIGATE ESUS randomized trial

Hart, Robert G.
Sharma, Mukul
Mundl, Hardi
Shoamanesh, Ashkan
Kasner, Scott E.
Berkowitz, Scott D.
Pare, Guillaume
Kirsch, Bodo
Pogue, Janice
Pater, Calin
Peters, Gary
Davalos, Antoni
Lang, Wilfried
Wang, Yilong
Cunha, Luis
Eckstein, Jens
Tatlisumak, Turgut
Shamalov, Nikolay
Mikulik, Robert
Lavados, Pablo
Hankey, Graeme J.
Czlonkowska, Anna
Toni, Danilo
Ameriso, Sebastian F.
Gagliardi, Rubens J.
Amarenco, Pierre
Bereczki, Daniel
Uchiyama, Shinichiro
Lindgren, Arne
Endres, Matthias
Brouns, Raf
Yoon, Byung Woo
Ntaios, George
Veltkamp, Roland
Muir, Keith W.
Ozturk, Serefnur
Arauz, Antonio
Bornstein, Natan
Bryer, Alan
O’Donnell, Martin J.
Weitz, Jeffrey
Peacock, Frank
Themeles, Ellison
Connolly, Stuart J.

January 2016

Background: Embolic strokes of undetermined source comprise up to 20% of ischemic strokes. The strok...

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.

Camm, AJ
Amarenco, P
Haas, S
Hess, S
Kirchhof, P
van Eickels, M
Turpie, AG

July 2014

Atrial fibrillation (AF) is associated with a fivefold increase in the risk of stroke. The Phase III...

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)

Gibson, C.M.
Mehran, R.
Bode, C.
Halperin, J.
Verheugt, F.W.A.
Wildgoose, P.
Eickels, M. van
Lip, G.Y.
Cohen, M.
Husted, S.
Peterson, E.
Fox, K.

January 2015

BACKGROUND: Guidelines recommendations regarding anticoagulant therapy after percutaneous coronary i...

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF

Hankey, GJ
Patel, MR
Stevens, SR
Becker, RC
Breithardt, G
Carolei, A
Diener, H-C
Donnan, GA
Halperin, JL
Mahaffey, KW
Mas, J-L
Massaro, A
Norrving, B
Nessel, CC
Paolini, JF
Roine, RO
Singer, DE
Wong, L
Califf, RM
Fox, KAA
Hacke, W

April 2012

C1 - Journal Articles RefereedBACKGROUND: In ROCKET AF, rivaroxaban was non-inferior to adjusted-dos...

Rivaroxabán versus warfarina en la fibrilación auricular no valvular

Patel, Manesh
Mahaffey, Kenneth
Garg, Jyotsna
Pan, Guohua
Singer, Daniel
Hacke, Werner
Breithardt, Gunter
Halperin, Jonathan
Hankey, Graeme
Piccini, Jonathan
Becker, Richard
Nessel, Christopher

August 2020

BACKGROUND The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillat...

Does Rivaroxaban Better than Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing PCI?

Maamar Kara
Omar Aitmokhtar
Adel Azaza
Saber Seddiki
Faiza Harbi
Arezki Sik
Kheireddine Merad
Salim Benkhedda

December 2016

ACS: Acute Coronary Syndrome; AF: Atrial Fibrillation; DAPT: Dual Antiplatelet Therapy; INR: Interna...

Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial

김영대

October 2017

Importance: In atrial fibrillation (AF)-related acute ischemic stroke, the optimal oral anticoagula...

Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.

Gibson, C.M.
Mega, J.L.
Burton, P.
Goto, S.
Verheugt, F.W.A.
Bode, C.
Plotnikov, A.
Sun, X.
Cook-Bruns, N.
Braunwald, E.

January 2011

BACKGROUND: Although therapy with aspirin or aspirin plus a thienopyridine reduces the incidence of ...

Methods Design: Randomized controlled trial (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in

Abstract

Extracted data

Methods Design: Randomized controlled trial (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in

Abstract

Extracted data

Related items

Related items